Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Zoledronate after denosumab discontinuation: Is repeated administrations more effective than single infusion?
CONCLUSIONS: In patients with uncontrolled CTX levels after Dmab withdrawal, two ZOL infusions at 6 months apart do not prevent BMD loss and FX.PMID:38609157 | DOI:10.1210/clinem/dgae224 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Giorgia Grassi Alberto Ghielmetti Marta Zampogna Iacopo Chiodini Maura Arosio Giovanna Mantovani Cristina Eller Vainicher Source Type: research
Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis
CONCLUSION: BMD remained stable in women with PremenIOP who received bisphosphonates after sequential teriparatide-denosumab therapy.PMID:38605469 | DOI:10.1210/clinem/dgae240 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Mafo Kamanda-Kosseh Stephanie Shiau Sanchita Agarwal Ananya Kondapalli Ivelisse Colon Nayoung Kil Mariana Bucovsky Joan M Lappe Julie Stubby Elizabeth Shane Adi Cohen Source Type: research
Zoledronate after denosumab discontinuation: Is repeated administrations more effective than single infusion?
CONCLUSIONS: In patients with uncontrolled CTX levels after Dmab withdrawal, two ZOL infusions at 6 months apart do not prevent BMD loss and FX.PMID:38609157 | DOI:10.1210/clinem/dgae224 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 12, 2024 Category: Endocrinology Authors: Giorgia Grassi Alberto Ghielmetti Marta Zampogna Iacopo Chiodini Maura Arosio Giovanna Mantovani Cristina Eller Vainicher Source Type: research
GSE248774 Immune modulation with RANKL-blockade through denosumab treatment in cancer patients
We examined whether administering denosumab could modify modulate circulating immune cells in c ancer patients. Blood was collected from 23 prostate cancer patients and 3 renal cell carcinoma patients, who provided written informed consent, with advanced disease who were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T cell repertoire and the frequency of new thymic emigrants with denosumab treatment. H...
Source: GEO: Gene Expression Omnibus - April 10, 2024 Category: Genetics & Stem Cells Tags: Other Homo sapiens Source Type: research
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
CONCLUSION: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.PMID:38594593 | DOI:10.1007/s00432-024-05663-z (Source: Cell Research)
Source: Cell Research - April 9, 2024 Category: Cytology Authors: Andrey Soares Fernando Sabino Marques Monteiro Karine Martins da Trindade Adriano Gon çalves E Silva Ana Paula Garcia Cardoso Andr é Deeke Sasse Andr é P Fay Andr é Paternò Castello Dias Carneiro Antonio Machado Alencar Junior Augusto C ésar de Andr Source Type: research
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
ConclusionImmunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature. (Source: Journal of Cancer Research and Clinical Oncology)
Source: Journal of Cancer Research and Clinical Oncology - April 9, 2024 Category: Cancer & Oncology Source Type: research
Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials
ConclusionData suggest support for the efficacy and safety of continuing romosozumab treatment following fracture.Trial registrationsNCT01575834; NCT01631214. (Source: Osteoporosis International)
Source: Osteoporosis International - April 4, 2024 Category: Orthopaedics Source Type: research
Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab
CONCLUSIONS: Therapeutic antibody interference in patients receiving isatuximab is common, and can persist for at least 8 weeks after administration. >10 % of patients receiving isatuximab may benefit from HYDRASHIFT testing post-therapy. In contrast, BM and denosumab fail to produce sustained interference in treated patients.PMID:38565341 | DOI:10.1016/j.clinbiochem.2024.110761 (Source: Clinical Biochemistry)
Source: Clinical Biochemistry - April 2, 2024 Category: Biochemistry Authors: Adam Jimenez Ashley Rose Scholl Bangchen Wang Michael Schilke Eric D Carlsen Source Type: research
Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab
CONCLUSIONS: Therapeutic antibody interference in patients receiving isatuximab is common, and can persist for at least 8 weeks after administration. >10 % of patients receiving isatuximab may benefit from HYDRASHIFT testing post-therapy. In contrast, BM and denosumab fail to produce sustained interference in treated patients.PMID:38565341 | DOI:10.1016/j.clinbiochem.2024.110761 (Source: Clinical Biochemistry)
Source: Clinical Biochemistry - April 2, 2024 Category: Biochemistry Authors: Adam Jimenez Ashley Rose Scholl Bangchen Wang Michael Schilke Eric D Carlsen Source Type: research
Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab
CONCLUSIONS: Therapeutic antibody interference in patients receiving isatuximab is common, and can persist for at least 8 weeks after administration. >10 % of patients receiving isatuximab may benefit from HYDRASHIFT testing post-therapy. In contrast, BM and denosumab fail to produce sustained interference in treated patients.PMID:38565341 | DOI:10.1016/j.clinbiochem.2024.110761 (Source: Clinical Biochemistry)
Source: Clinical Biochemistry - April 2, 2024 Category: Biochemistry Authors: Adam Jimenez Ashley Rose Scholl Bangchen Wang Michael Schilke Eric D Carlsen Source Type: research
The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena
ConclusionIn our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implement ation. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - April 2, 2024 Category: Orthopaedics Source Type: research
The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena
ConclusionIn our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implement ation. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - April 2, 2024 Category: Orthopaedics Source Type: research
Denosumab
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research
